The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 1, 2009, Pages 191-195

  Dredge, K ^a   Kink, J A ^b   Johnson, R M ^c   Bytheway, I ^a   Marton, L J ^d  

^a Progen Pharmaceuticals Limited   (Australia)

^b Quintessence Biosciences Inc   (United States)

^c KAI Pharmaceuticals   (United States)

^d Progen Pharmaceuticals   (United States)

Author keywords

Bevacizumab; Cancer therapy; Cisplatin; PG11047; Polyamine analog

Indexed keywords

BEVACIZUMAB; CISPLATIN; PG 11047; POLYAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TOLERABILITY; LUNG CANCER; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE; WEIGHT GAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CELL LINE, TUMOR; CISPLATIN; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; POLYAMINES; PROSTATIC NEOPLASMS;

EID: 70349621130     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1105-7     Document Type: Article

References (25)

1. O Heby 1981 Role of polyamines in the control of cell proliferation and differentiation Differentiation 19 1 20 6173280 10.1111/j.1432-0436.1981. tb01123.x 1:CAS:528:DyaL3MXktlOht7w%3D (Pubitemid 11091193)
2. J Janne L Alhonen P Leinonen 1991 Polyamines: from molecular biology to clinical applications Ann Med 23 241 259 1930914 10.3109/07853899109148056 1:CAS:528:DyaK3MXmslemsbo%3D
3. CW Tabor H Tabor 1984 Polyamines Annu Rev Biochem 53 749 790 6206782 10.1146/annurev.bi.53.070184.003533 1:CAS:528:DyaL2cXlt1Cqtb0%3D
4. K Igarashi K Kashiwagi 2000 Polyamines: mysterious modulators of cellular functions Biochem Biophys Res Commun 271 559 564 10814501 10.1006/bbrc.2000. 2601 1:CAS:528:DC%2BD3cXjt1SjsrY%3D (Pubitemid 30444667)
5. S Matsufuji T Matsufuji Y Miyazaki, et al. 1995 Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme Cell 80 51 60 7813017 10.1016/0092-8674(95)90450-6 1:CAS:528:DyaK2MXjtFegur4%3D
6. RA Casero Jr LJ Marton 2007 Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases Nat Rev Drug Discov 6 373 390 17464296 10.1038/nrd2243 1:CAS:528:DC%2BD2sXkslyiu7k%3D (Pubitemid 46705201)
7. N Seiler 2005 Pharmacological aspects of cytotoxic polyamine analogs and derivatives for cancer therapy Pharmacol Ther 107 99 119 15963353 10.1016/j.pharmthera.2005.02.001 1:CAS:528:DC%2BD2MXlt1Ghu78%3D (Pubitemid 40803509)
8. VK Reddy A Valasinas A Sarkar, et al. 1998 Conformationally restricted analogues of 1N, 12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines J Med Chem 41 4723 4732 9822543 10.1021/jm980172v 1:CAS:528:DyaK1cXmvVaqt7k%3D (Pubitemid 28530449)
9. A Valasinas A Sarkar VK Reddy, et al. 2001 Conformationally restricted analogues of 1N, 14N-bisethylhomospermine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells J Med Chem 44 390 403 11462979 10.1021/jm000309t 1:CAS:528:DC%2BD3cXovVWmsr4%3D (Pubitemid 32113585)
10. Y Huang A Pledgie RA Casero, et al. 2005 Molecular mechanisms of polyamine analogs in cancer cells Anticancer Drugs 16 229 241 15711175 10.1097/00001813-200503000-00002 1:CAS:528:DC%2BD2MXht1Omsbk%3D (Pubitemid 40283938)
11. CM Holst B Frydman LJ Marton SM Oredsson 2006 Differential polyamine analogue effects in four human breast cancer cell lines Toxicology 223 71 81 16697514 10.1016/j.tox.2006.03.009 1:CAS:528:DC%2BD28XkvVynt7o%3D (Pubitemid 43728619)
12. A Hacker LJ Marton M Sobolewski RA Casero Jr 2008 In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells Cancer Chemother Pharmacol 63 1 45 53 18301893 10.1007/s00280-008-0706-x 1:CAS:528:DC%2BD1cXhtF2kur7P
13. JL Mitchell TK Thane JM Sequeira, et al. 2007 Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs Amino Acids 33 291 297 17410332 10.1007/s00726-007-0523-2 1:CAS:528: DC%2BD2sXos1eqtrY%3D (Pubitemid 47222969)
14. HC Ha PM Woster JD Yager, et al. 1997 The role of polyamine catabolism in polyamine analogue-induced programmed cell death Proc Natl Acad Sci USA 94 11557 11662 9326648 10.1073/pnas.94.21.11557 1:CAS:528:DyaK2sXmslaqtr4%3D (Pubitemid 27451037)
15. Y Wang W Devereux PM Woster 2001 Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure Cancer Res 61 5370 5373 11454677 1:CAS:528:DC%2BD3MXlsVChsrk%3D
16. Y Wang T Murray-Stewart W Devereux 2003 Properties of purified recombinant human polyamine oxidase PAOh/SMO Biochem Biophys Res Commun 304 605 611 12727196 10.1016/S0006-291X(03)00636-3 1:CAS:528:DC%2BD3sXjtlWmur4%3D (Pubitemid 36513529)
17. W Devereux Y Wang TM Stewart 2003 Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells Cancer Chemother Pharmacol 52 5 383 390 12827295 10.1007/s00280-003-0662-4 1:CAS:528: DC%2BD3sXotFWmtL8%3D (Pubitemid 37363611)
18. TR Hawthorn JK Austin Jr 1996 Synergism of the polyamine analogue, N1, N11-bisethylnorspermine with cis-diaminedichloroplatinum (II) against murine neoplastic cell lines in vitro and in vivo Cancer Lett 99 1 99 107 10.1016/0304-3835(95)04043-9
19. KJ Svensson JE Welch P Kucharzewska 2008 Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase Cancer Res 68 22 9291 9301 19010902 10.1158/0008-5472.CAN-08-2340 1:CAS:528:DC%2BD1cXhtlOmt7rL
20. HM Wallace AV Fraser A Hughes 2003 A perspective of polyamine metabolism Biochem J 376 1 14 13678416 10.1042/BJ20031327 1:CAS:528:DC%2BD3sXovVajs7Y%3D (Pubitemid 37487199)
21. WC Liang X Wu FV Peale, et al. 2006 Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF J Biol Chem 281 2 951 961 16278208 10.1074/jbc.M508199200 1:CAS:528:DC%2BD28Xit1Witw%3D%3D
22. WL Allen EG McLean J Boyer, et al. 2007 The role of spemidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells Mol Cancer Ther 6 1 128 137 17237273 10.1158/1535-7163.MCT-06-0303 1:CAS:528:DC%2BD2sXmsVanug%3D%3D (Pubitemid 46206675)
23. R Varma S Hector WR Greco, et al. 2007 Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells Cancer Chemother Pharmacol 59 711 723 17021820 10.1007/s00280-006-0325-3 1:CAS:528:DC%2BD2sXjt1WmtL0%3D (Pubitemid 46440593)
24. RF Morrison ER Seidel 1995 Vascular endothelial cell proliferation: regulation of cellular polyamines Cardiovasc Res 29 841 847 7656288 1:CAS:528:DyaK2MXnt1eqt7s%3D
25. JS Carew ST Nawrocki VK Reddy, et al. 2008 The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib Cancer Res 68 4783 4790 18559525 10.1158/0008-5472.CAN-07-6483 1:CAS:528:DC%2BD1cXnt1ejs7g%3D